Hemlibra Side Effects

Generic name: emicizumab

Medically reviewed by Drugs.com. Last updated on Jul 14, 2024.

Note: This document provides detailed information about Hemlibra Side Effects associated with emicizumab. Some dosage forms listed on this page may not apply specifically to the brand name Hemlibra.

Applies to emicizumab: subcutaneous solution.

Important warnings This medicine can cause some serious health issues

Subcutaneous route (solution)

Warning: Thrombotic Microangiopathy and Thromboembolism. Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of greater than 100 units/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving emicizumab-kxwh prophylaxis.

Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered.

Discontinue aPCC and suspend dosing of emicizumab-kxwh if symptoms occur.

Common side effects of Hemlibra

Some side effects of emicizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
• headache
• diarrhea
• difficulty in moving
• fever
• joint pain or swelling
• muscle aches, cramps, pain, or stiffness
• muscle pain or stiffness

Serious side effects of Hemlibra

Along with its needed effects, emicizumab (the active ingredient contained in Hemlibra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking emicizumab:

Incidence not known

• blue-green to black skin discoloration
• changes in skin color, pain, tenderness, or swelling of the foot or leg
• pain, redness, or sloughing of the skin at the injection site
• sudden weakness in the arms or legs
• sudden, severe chest pain

For healthcare professionals

Applies to emicizumab: subcutaneous solution.

General adverse events

The most common adverse reactions were injection site reactions, antibody formation, headache, injection site erythema, and arthralgia.^[Ref]

Cardiovascular

• Common (1% to 10%): Thrombotic microangiopathy, thrombotic events
• Frequency not reported: Superficial thrombophlebitis^[Ref]

Local

• Very common (10% or more): Injection site reactions (22%), injection site erythema (11%)
• Common (1% to 10%): Injection site pain, injection site pruritus^[Ref]

Nervous system

• Very common (10% or more): Headache (15%)^[Ref]

Musculoskeletal

• Very common (10% or more): Arthralgia (10%)
• Common (1% to 10%): Myalgia
• Uncommon (0.1% to 1%): Rhabdomyolysis, serum creatine kinase elevated^[Ref]

Gastrointestinal

• Common (1% to 10%): Diarrhea^[Ref]

Immunologic

• Very common (10% or more): Antibody formation (up to 22%)^[Ref]

Other

• Common (1% to 10%): Pyrexia^[Ref]

Dermatologic

• Frequency not reported: Skin necrosis^[Ref]

Further information

Hemlibra side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer